ABSI NASDAQ
Absci Corporation
1W: -7.3%
1M: -25.9%
3M: +91.9%
YTD: +109.4%
1Y: +115.4%
3Y: +246.8%
$7.13
-0.43 (-5.69%)
Weekly Expected Move ±11.2%
$6
$7
$8
$8
$9
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.8M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.2B
52W Range2.24-12.055
Volume2,849,679
Avg Volume5,706,813
Beta2.33
Dividend—
Analyst Ratings
Company Info
CEOSean McClain
Employees140
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-22
Websiteabsci.com
18105 SE Mill Plain Boulevard
Vancouver, WA 98683
US
Vancouver, WA 98683
US
360 949 1041
About Absci Corporation
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Latest News
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
Absci sets 4:30 p.m. ET webcast for its Aug. 11 Q2 update - Stock Titan
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Szela Mary T | P-Purchase | 12,900 | $11.54 | 2026-06-30 |
| McClain Sean | F-InKind | 59,896 | $10.07 | 2026-06-24 |
| Szela Mary T | A-Award | 8,400 | — | 2026-06-04 |
| Szela Mary T | A-Award | 33,200 | $7.34 | 2026-06-04 |
| MCGINNIS KAREN K | A-Award | 10,100 | — | 2026-06-04 |